Clariant Healthcare Packaging to Build New Plant in India
News Dec 04, 2015
Clariant has announced plans to invest CHF 10 million in a new Healthcare Packaging manufacturing plant in Cuddalore in Tamil Nadu State, located about 25 km from the city of Puducherry. The plant will manufacture Clariant's market-leading moisture control products to support the growing pharmaceutical packaging market in India.
"India is the largest provider of generic drugs globally," says Ketan Premani, Head of Clariant Healthcare Packaging Sales in India, "making it a key market for Clariant's desiccant products. We want to ensure that we serve our customers here as directly and efficiently as possible. When the plant is complete, they will now have the ability to procure Clariant's global-standard products directly produced in India."
Clariant Healthcare Packaging, a member of Business Unit Masterbatches, manufactures a full range of controlled atmosphere packaging solutions including pharmaceutical desiccants, equilibrium sorbents, adsorbent polymers, oxygen scavengers and pharmaceutical closures and containers.
The new plant in Cuddalore will initially produce desiccant canisters and packets, which are inserted into pharmaceutical packaging to control moisture and protect the stability of the medicine during shelf life. The desiccant production area will be Clean Room Class 100,000 and certified ISO 8. It will be compliant with all relevant cGMP and US FDA standards.
Dr. Deepak Parikh, Region President – India, Clariant, said, "We are happy to announce our plans to invest in a new state-of-the-art manufacturing plant in India. This new manufacturing facility is in alignment with our overall growth strategy in the country. The new facility will enable us to enhance our medical specialties business and offer end-to-end solutions to our existing as well as potential customers. Clariant in India is accelerating change and continues to fulfil our commitments to all our stakeholders, as the Indian market stays at the core of Clariant's global focus."
The new plant will primarily serve globally active generic and branded pharmaceutical companies operating in India, as well as the domestic Indian pharmaceutical market. According to Markets and Markets, a major global market-research firm, India's pharmaceutical packaging market is projected to grow at a compounded annual growth rate (CAGR) of 10.2 percent from 2015 to 2020.
India Ratings & Research, another research company with six offices across India, recently reported that Indian drug makers accounted for 40 percent of U.S. generic drug imports. It forecasts a 20 percent CAGR for the overall pharmaceutical market through 2020.
The new Healthcare Packaging plant in Cuddalore—together with its plant in Changshu, China and the recent acquisition of healthcare packaging specialist VitaPac, located in Dongguan, China—positions Clariant to play a major role in the expanding healthcare sector across Asia.
Creating another base for desiccant canister and packet production also supports Clariant's rigorous business-continuity goals. "More and more global pharmaceutical companies are instituting business-continuity plans, or BCP, to deal with possible market disruptions, both natural and man-made," explains Matthias Brommer, Vice President and Head of Clariant Healthcare Packaging. "This new plant will support our ability to provide the same products from multiple plants in Asia and around the world."
"The significant investment in Cuddalore of our new Healthcare Packaging plant further strengthens our commitment to capture the growth opportunities that exist in emerging markets and specifically in the highly attractive market in India," stated Marco Cenisio, Senior Vice President and General Manager of Business Unit Masterbatches. "It also highlights the commitment of our Business Unit to devote a large portion of the capital budget to our Healthcare Packaging business to continue to fund its growth."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE